Thyrocare Technologies Limited (THYROCARE.NS)
INR 708.6
(0.34%)
INR 708.6
(0.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 2.5 Billion INR | -31.13% |
| 2022 | 3.63 Billion INR | -13.3% |
| 2021 | 4.19 Billion INR | 26.74% |
| 2020 | 3.3 Billion INR | 4.62% |
| 2019 | 3.16 Billion INR | 8.12% |
| 2018 | 2.92 Billion INR | 11.88% |
| 2017 | 2.61 Billion INR | 20.17% |
| 2016 | 2.17 Billion INR | 29.92% |
| 2015 | 1.67 Billion INR | 34.3% |
| 2014 | 1.24 Billion INR | 32.14% |
| 2013 | 943.31 Million INR | 7.1% |
| 2012 | 880.79 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.26 Billion INR | 17.43% |
| 2024 Q1 | 713.7 Million INR | 4.88% |
| 2023 Q4 | 680.5 Million INR | -29.35% |
| 2023 Q1 | 968.2 Million INR | 2.86% |
| 2023 FY | 2.5 Billion INR | -31.13% |
| 2023 Q3 | 963.2 Million INR | -7.7% |
| 2023 Q2 | 1.04 Billion INR | 7.79% |
| 2022 Q2 | 938.5 Million INR | 6.3% |
| 2022 Q4 | 941.3 Million INR | 7.98% |
| 2022 FY | 3.63 Billion INR | -13.3% |
| 2022 Q1 | 882.9 Million INR | -0.43% |
| 2022 Q3 | 871.7 Million INR | -7.12% |
| 2021 Q3 | 874 Million INR | -34.09% |
| 2021 Q2 | 1.32 Billion INR | 20.08% |
| 2021 Q1 | 1.1 Billion INR | 7.79% |
| 2021 FY | 4.19 Billion INR | 26.74% |
| 2021 Q4 | 886.7 Million INR | 1.45% |
| 2020 Q4 | 1.02 Billion INR | 7.2% |
| 2020 FY | 3.3 Billion INR | 4.62% |
| 2020 Q3 | 955.7 Million INR | -6.67% |
| 2020 Q2 | 1.02 Billion INR | 237.84% |
| 2020 Q1 | 303.1 Million INR | -59.0% |
| 2019 FY | 3.16 Billion INR | 8.12% |
| 2019 Q1 | 788.7 Million INR | 5.19% |
| 2019 Q2 | 850.3 Million INR | 7.81% |
| 2019 Q3 | 782.9 Million INR | -7.93% |
| 2019 Q4 | 739.2 Million INR | -5.58% |
| 2018 Q3 | 703.4 Million INR | -6.85% |
| 2018 FY | 2.92 Billion INR | 11.88% |
| 2018 Q2 | 755.1 Million INR | 5.53% |
| 2018 Q1 | 715.5 Million INR | 1.24% |
| 2018 Q4 | 749.8 Million INR | 6.6% |
| 2017 FY | 2.61 Billion INR | 20.17% |
| 2017 Q4 | 706.73 Million INR | 11.99% |
| 2017 Q3 | 631.05 Million INR | 1.56% |
| 2017 Q2 | 621.34 Million INR | -5.04% |
| 2017 Q1 | 654.3 Million INR | 4.9% |
| 2016 Q3 | 479.05 Million INR | -13.56% |
| 2016 Q2 | 554.21 Million INR | 13.14% |
| 2016 Q1 | 489.83 Million INR | -0.73% |
| 2016 Q4 | 623.72 Million INR | 30.2% |
| 2016 FY | 2.17 Billion INR | 29.92% |
| 2015 Q4 | 493.43 Million INR | 28.34% |
| 2015 Q2 | 442.43 Million INR | 11.71% |
| 2015 Q1 | 396.06 Million INR | 0.0% |
| 2015 FY | 1.67 Billion INR | 34.3% |
| 2015 Q3 | 384.47 Million INR | -13.1% |
| 2014 FY | 1.24 Billion INR | 32.14% |
| 2013 FY | 943.31 Million INR | 7.1% |
| 2012 FY | 880.79 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Krsnaa Diagnostics Limited | 4.13 Billion INR | 39.411% |
| Dr. Lal PathLabs Limited | 14.62 Billion INR | 82.881% |
| Metropolis Healthcare Limited | 5.81 Billion INR | 56.94% |
| Vijaya Diagnostic Centre Limited | 4.82 Billion INR | 48.108% |
| Vimta Labs Limited | 986.72 Million INR | -153.679% |